Based on the provided transcript, the short-term implications for Amgen Inc. are mixed. The company reported strong financial results, with revenues up 6% year over year and adjusted earnings per share up 13%. The management team highlighted progress in several key therapeutic areas, including cardiovascular disease, cancer, and multiple myeloma. However, there were some concerns raised about the potential impact of biosimilar competition on certain products, as well as the uncertainty surrounding the proposed Part B changes and the dynamics of share loss in the 340B hospital setting. Overall, the stock is likely to face short-term pressure due to the uncertainty surrounding these factors, but the company's strong financial performance and progress in key therapeutic areas suggest long-term potential.